Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy

Uxía Nogueira-Recalde, Irene Lorenzo-Gómez, Francisco J. Blanco, María I. Loza, Diego Grassi, Valery Shirinsky, Ivan Shirinsky, Martin Lotz, Paul D. Robbins, Eduardo Domínguez, Beatriz Caramés

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: Ageing-related failure of homeostasis mechanisms contributes to articular cartilage degeneration and osteoarthritis (OA), for which disease-modifying treatments are not available. Our objective was to identify molecules to prevent OA by regulating chondrocyte senescence and autophagy. Methods: Human chondrocytes with IL-6 induced senescence and autophagy suppression and SA-β-gal as a reporter of senescence and LC3 as reporter of autophagic flux were used to screen the Prestwick Chemical Library of approved drugs. Preclinical cellular, tissue and blood from OA and blood from OA and ageing models were used to test the efficacy and relevance of activating PPARα related to cartilage degeneration. Findings: Senotherapeutic molecules with pro-autophagic activity were identified. Fenofibrate (FN), a PPARα agonist used for dyslipidaemias in humans, reduced the number of senescent cells via apoptosis, increased autophagic flux, and protected against cartilage degradation. FN reduced both senescence and inflammation and increased autophagy in both ageing human and OA chondrocytes whereas PPARα knockdown conferred the opposite effect. Moreover, PPARα expression was reduced through both ageing and OA in mice and also in blood and cartilage from knees of OA patients. Remarkably, in a retrospective study, fibrate treatment improved OA clinical conditions in human patients from the Osteoarthritis Initiative (OAI) Cohort. Interpretation: These results demonstrate that FDA-approved fibrate drugs targeting lipid metabolism protect against cartilage degeneration seen with ageing and OA. Thus, these drugs could have immediate clinically utility for age-related cartilage degeneration and OA treatment. Fund: This study was supported by Instituto de Salud Carlos III- Ministerio de Ciencia, Innovación y Universidades, Spain, Plan Estatal 2013–2016 and Fondo Europeo de Desarrollo Regional (FEDER), “Una manera de hacer Europa”, PI14/01324 and PI17/02059, by Innopharma Pharmacogenomics platform applied to the validation of targets and discovery of drugs candidates to preclinical phases, Ministerio de Economía y Competitividad, by grants of the National Instiutes of Health to PDR (P01 AG043376 and U19 AG056278). We thank FOREUM Foundation for Research in Rheumatology for their support.

Original languageEnglish (US)
Pages (from-to)588-605
Number of pages18
JournalEBioMedicine
Volume45
DOIs
StatePublished - Jul 2019

Fingerprint

Fibric Acids
Cartilage
Osteoarthritis
Peroxisome Proliferator-Activated Receptors
Aging of materials
Pharmaceutical Preparations
Fenofibrate
Blood
Autophagy
Chondrocytes
Therapeutics
Fluxes
Molecules
Interleukin-6
Small Molecule Libraries
Health
Tissue
Apoptosis
Organized Financing
Knee Osteoarthritis

Keywords

  • Ageing
  • Autophagy
  • Osteoarthritis
  • Screening
  • Senescence
  • Therapeutics

Cite this

Nogueira-Recalde, U., Lorenzo-Gómez, I., Blanco, F. J., Loza, M. I., Grassi, D., Shirinsky, V., ... Caramés, B. (2019). Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy. EBioMedicine, 45, 588-605. https://doi.org/10.1016/j.ebiom.2019.06.049

Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy. / Nogueira-Recalde, Uxía; Lorenzo-Gómez, Irene; Blanco, Francisco J.; Loza, María I.; Grassi, Diego; Shirinsky, Valery; Shirinsky, Ivan; Lotz, Martin; Robbins, Paul D.; Domínguez, Eduardo; Caramés, Beatriz.

In: EBioMedicine, Vol. 45, 07.2019, p. 588-605.

Research output: Contribution to journalArticle

Nogueira-Recalde, U, Lorenzo-Gómez, I, Blanco, FJ, Loza, MI, Grassi, D, Shirinsky, V, Shirinsky, I, Lotz, M, Robbins, PD, Domínguez, E & Caramés, B 2019, 'Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy', EBioMedicine, vol. 45, pp. 588-605. https://doi.org/10.1016/j.ebiom.2019.06.049
Nogueira-Recalde U, Lorenzo-Gómez I, Blanco FJ, Loza MI, Grassi D, Shirinsky V et al. Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy. EBioMedicine. 2019 Jul;45:588-605. https://doi.org/10.1016/j.ebiom.2019.06.049
Nogueira-Recalde, Uxía ; Lorenzo-Gómez, Irene ; Blanco, Francisco J. ; Loza, María I. ; Grassi, Diego ; Shirinsky, Valery ; Shirinsky, Ivan ; Lotz, Martin ; Robbins, Paul D. ; Domínguez, Eduardo ; Caramés, Beatriz. / Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy. In: EBioMedicine. 2019 ; Vol. 45. pp. 588-605.
@article{74fbae1f97924b66836c75a28bedacbe,
title = "Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy",
abstract = "Background: Ageing-related failure of homeostasis mechanisms contributes to articular cartilage degeneration and osteoarthritis (OA), for which disease-modifying treatments are not available. Our objective was to identify molecules to prevent OA by regulating chondrocyte senescence and autophagy. Methods: Human chondrocytes with IL-6 induced senescence and autophagy suppression and SA-β-gal as a reporter of senescence and LC3 as reporter of autophagic flux were used to screen the Prestwick Chemical Library of approved drugs. Preclinical cellular, tissue and blood from OA and blood from OA and ageing models were used to test the efficacy and relevance of activating PPARα related to cartilage degeneration. Findings: Senotherapeutic molecules with pro-autophagic activity were identified. Fenofibrate (FN), a PPARα agonist used for dyslipidaemias in humans, reduced the number of senescent cells via apoptosis, increased autophagic flux, and protected against cartilage degradation. FN reduced both senescence and inflammation and increased autophagy in both ageing human and OA chondrocytes whereas PPARα knockdown conferred the opposite effect. Moreover, PPARα expression was reduced through both ageing and OA in mice and also in blood and cartilage from knees of OA patients. Remarkably, in a retrospective study, fibrate treatment improved OA clinical conditions in human patients from the Osteoarthritis Initiative (OAI) Cohort. Interpretation: These results demonstrate that FDA-approved fibrate drugs targeting lipid metabolism protect against cartilage degeneration seen with ageing and OA. Thus, these drugs could have immediate clinically utility for age-related cartilage degeneration and OA treatment. Fund: This study was supported by Instituto de Salud Carlos III- Ministerio de Ciencia, Innovaci{\'o}n y Universidades, Spain, Plan Estatal 2013–2016 and Fondo Europeo de Desarrollo Regional (FEDER), “Una manera de hacer Europa”, PI14/01324 and PI17/02059, by Innopharma Pharmacogenomics platform applied to the validation of targets and discovery of drugs candidates to preclinical phases, Ministerio de Econom{\'i}a y Competitividad, by grants of the National Instiutes of Health to PDR (P01 AG043376 and U19 AG056278). We thank FOREUM Foundation for Research in Rheumatology for their support.",
keywords = "Ageing, Autophagy, Osteoarthritis, Screening, Senescence, Therapeutics",
author = "Ux{\'i}a Nogueira-Recalde and Irene Lorenzo-G{\'o}mez and Blanco, {Francisco J.} and Loza, {Mar{\'i}a I.} and Diego Grassi and Valery Shirinsky and Ivan Shirinsky and Martin Lotz and Robbins, {Paul D.} and Eduardo Dom{\'i}nguez and Beatriz Caram{\'e}s",
year = "2019",
month = "7",
doi = "10.1016/j.ebiom.2019.06.049",
language = "English (US)",
volume = "45",
pages = "588--605",
journal = "EBioMedicine",
issn = "2352-3964",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Fibrates as drugs with senolytic and autophagic activity for osteoarthritis therapy

AU - Nogueira-Recalde, Uxía

AU - Lorenzo-Gómez, Irene

AU - Blanco, Francisco J.

AU - Loza, María I.

AU - Grassi, Diego

AU - Shirinsky, Valery

AU - Shirinsky, Ivan

AU - Lotz, Martin

AU - Robbins, Paul D.

AU - Domínguez, Eduardo

AU - Caramés, Beatriz

PY - 2019/7

Y1 - 2019/7

N2 - Background: Ageing-related failure of homeostasis mechanisms contributes to articular cartilage degeneration and osteoarthritis (OA), for which disease-modifying treatments are not available. Our objective was to identify molecules to prevent OA by regulating chondrocyte senescence and autophagy. Methods: Human chondrocytes with IL-6 induced senescence and autophagy suppression and SA-β-gal as a reporter of senescence and LC3 as reporter of autophagic flux were used to screen the Prestwick Chemical Library of approved drugs. Preclinical cellular, tissue and blood from OA and blood from OA and ageing models were used to test the efficacy and relevance of activating PPARα related to cartilage degeneration. Findings: Senotherapeutic molecules with pro-autophagic activity were identified. Fenofibrate (FN), a PPARα agonist used for dyslipidaemias in humans, reduced the number of senescent cells via apoptosis, increased autophagic flux, and protected against cartilage degradation. FN reduced both senescence and inflammation and increased autophagy in both ageing human and OA chondrocytes whereas PPARα knockdown conferred the opposite effect. Moreover, PPARα expression was reduced through both ageing and OA in mice and also in blood and cartilage from knees of OA patients. Remarkably, in a retrospective study, fibrate treatment improved OA clinical conditions in human patients from the Osteoarthritis Initiative (OAI) Cohort. Interpretation: These results demonstrate that FDA-approved fibrate drugs targeting lipid metabolism protect against cartilage degeneration seen with ageing and OA. Thus, these drugs could have immediate clinically utility for age-related cartilage degeneration and OA treatment. Fund: This study was supported by Instituto de Salud Carlos III- Ministerio de Ciencia, Innovación y Universidades, Spain, Plan Estatal 2013–2016 and Fondo Europeo de Desarrollo Regional (FEDER), “Una manera de hacer Europa”, PI14/01324 and PI17/02059, by Innopharma Pharmacogenomics platform applied to the validation of targets and discovery of drugs candidates to preclinical phases, Ministerio de Economía y Competitividad, by grants of the National Instiutes of Health to PDR (P01 AG043376 and U19 AG056278). We thank FOREUM Foundation for Research in Rheumatology for their support.

AB - Background: Ageing-related failure of homeostasis mechanisms contributes to articular cartilage degeneration and osteoarthritis (OA), for which disease-modifying treatments are not available. Our objective was to identify molecules to prevent OA by regulating chondrocyte senescence and autophagy. Methods: Human chondrocytes with IL-6 induced senescence and autophagy suppression and SA-β-gal as a reporter of senescence and LC3 as reporter of autophagic flux were used to screen the Prestwick Chemical Library of approved drugs. Preclinical cellular, tissue and blood from OA and blood from OA and ageing models were used to test the efficacy and relevance of activating PPARα related to cartilage degeneration. Findings: Senotherapeutic molecules with pro-autophagic activity were identified. Fenofibrate (FN), a PPARα agonist used for dyslipidaemias in humans, reduced the number of senescent cells via apoptosis, increased autophagic flux, and protected against cartilage degradation. FN reduced both senescence and inflammation and increased autophagy in both ageing human and OA chondrocytes whereas PPARα knockdown conferred the opposite effect. Moreover, PPARα expression was reduced through both ageing and OA in mice and also in blood and cartilage from knees of OA patients. Remarkably, in a retrospective study, fibrate treatment improved OA clinical conditions in human patients from the Osteoarthritis Initiative (OAI) Cohort. Interpretation: These results demonstrate that FDA-approved fibrate drugs targeting lipid metabolism protect against cartilage degeneration seen with ageing and OA. Thus, these drugs could have immediate clinically utility for age-related cartilage degeneration and OA treatment. Fund: This study was supported by Instituto de Salud Carlos III- Ministerio de Ciencia, Innovación y Universidades, Spain, Plan Estatal 2013–2016 and Fondo Europeo de Desarrollo Regional (FEDER), “Una manera de hacer Europa”, PI14/01324 and PI17/02059, by Innopharma Pharmacogenomics platform applied to the validation of targets and discovery of drugs candidates to preclinical phases, Ministerio de Economía y Competitividad, by grants of the National Instiutes of Health to PDR (P01 AG043376 and U19 AG056278). We thank FOREUM Foundation for Research in Rheumatology for their support.

KW - Ageing

KW - Autophagy

KW - Osteoarthritis

KW - Screening

KW - Senescence

KW - Therapeutics

UR - http://www.scopus.com/inward/record.url?scp=85068385233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068385233&partnerID=8YFLogxK

U2 - 10.1016/j.ebiom.2019.06.049

DO - 10.1016/j.ebiom.2019.06.049

M3 - Article

C2 - 31285188

AN - SCOPUS:85068385233

VL - 45

SP - 588

EP - 605

JO - EBioMedicine

JF - EBioMedicine

SN - 2352-3964

ER -